Aldehyde Dehydrogenase 1 (aldh1) Genes In Cancer Clinical Prognosis Outcomes by Ding, Mengyi
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Public Health Theses School of Public Health 
1-1-2016 
Aldehyde Dehydrogenase 1 (aldh1) Genes In Cancer Clinical 
Prognosis Outcomes 
Mengyi Ding 
Yale University, mengyi.ding@yale.edu 
Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl 
Recommended Citation 
Ding, Mengyi, "Aldehyde Dehydrogenase 1 (aldh1) Genes In Cancer Clinical Prognosis Outcomes" (2016). 
Public Health Theses. 1066. 
https://elischolar.library.yale.edu/ysphtdl/1066 
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – 
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an 
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, 





Aldehyde Dehydrogenase 1 (ALDH1) Genes in  








Class of 2016 
Department of Environmental Health Science 





First Reader: Vasilis Vasiliou, PhD 





Background & Hypothesis 
It has become clear that ALDH1 genes are involved in the pathobiology of various human cancers. 
Several lines of evidence indicated that ALDH1 gene expression in tumors may be associated with 
clinical prognosis outcomes. This hypothesis of our study is that ALDH1 genes may be used to predict 
human cancer prognosis. In order to test this hypothesis, a systematic review of published articles, a 
meta-analysis using Random-Effects model was conducted to assess the association between ALDH1 
genes and clinicopathological features as well as survival outcomes.  
 
Methods  
Using PubMed, EMBASE and Web of Science, this study identified original English researches targeted 
for association between ALDH1 genes and cancer prognosis for more than 20 patients during survival 
analysis follow-up. This meta-analysis included original studies that evaluated a major clinical 
outcomes (overall survival, disease progression, recurrence, and metastasis) in agnostic format for a 
variety of cancer types and ALDH1 genes. Association of ALDH1 expression and clinicopathological 
outcomes were evaluated using the Review Manager 5.3 software. 
 
Results 
One hundred and twenty one original researches were eligible for inclusion in this meta-analysis. 
ALDH1 expression was significantly associated with poor overall survival of breast cancer, colon cancer, 
non-small cell lung cancer, and ovarian cancer. ALDH1 expression was also associated with poor 
prognosis of disease-free survival of breast cancer, non-small cell lung cancer, and rectal cancer. This 
meta-analysis showed no association of ALDH1 expression with prognosis of esophageal squamous 
carcinoma and Head and Neck Squamous Cell Carcinoma (HNSCC).  
 
Conclusion 
Expression of ALDH1 genes is associated with poor prognosis of breast cancer, colon cancer, non-small 
cell lung cancer, ovarian cancer and rectal cancer.  
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Background and Rationale       
The human aldehyde dehydrogenase (ALDH) gene superfamily comprises nineteen genes that are 
classified into eleven families and four subfamilies family. The ALDH genes encode proteins (isozymes) 
that are catalytically-active, although some ALDH proteins appear to be catalytically-inactive. The 
ALDH gene family also play an important physiological role in encoding proteins, leading to the 
formation of either catalytically-active or catalytically-inactive proteins [1]. ALDH isoenzymes 
participate in numerous biological processes mainly by catalyzing the oxidation of a wide spectrum of 
aldehyde to carboxylic acids [2]. Aldehydes are highly reactive molecules that are generated during the 
metabolism of either endogenous (e.g., amino acids, neurotransmitters, and carbohydrates) or 
exogenous (cigarette smoke, food) agents [3]. The ALDH proteins ubiquitously exist in nearly all 
subcellular tissues [4], with the majority of the ALDHs broadly distributed in tissues and hence display 
distinct substrate specificity [5].  
 
Historically the ALDH1 and ALDH2 genes are the most commonly studied enzymes that are responsible 
for aldehyde oxidation and the enzymes have the highest concentration in the liver [6]. The significance 
of ALDHs in physiological processes is based on compelling evidence that mutations and genetic 
polymorphisms in ALDH genes are associated with phenotypes that extensively exist in humans and 
rodents [7], such as alcohol-related diseases [8], cancer [9] and other neuro and endocrine diseases  [10, 
11]. In addition to the association between mutations in ALDH genes and clinical phenotypes, studies 
with transgenic knockout mice further support the notion that ALDHs are crucial in less-studied 
physiological functions such as embryogenesis and development [12].     
      
The ALDH1 family is consists of six enzymes including ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, 
ALDH1L1 and ALDH1L2.  ALDH1 genes catalyzes the detoxification of endogenous as well as 
exogenous aldehydes, oxidization of retinol to synthesize retinoic acid [13]. ALDH1 is responsible for 
the oxidation of intracellular aldehydes [14], contributing to the oxidation of retinol to retinoic acid in 
stem cell differentiation process and has been widely identified as a novel tumor stem-like cell marker 
in malignancies. ALDH1 is highly expressed in many stem and progenitor cells in several tissue types, 
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which is believed to play a role in cancer [15]. As stem cells can asymmetrically divide into stem cell 
or progenitor cell, and cancer is often regarded as uncontrolled proliferation of such stem cell [16]. 
Hence ALDH1 may be a biomarker of stemness. To date, ALDH1 activity has been used as a stem cell 
marker for head and neck squamous cell carcinoma [17], lung cancer [18], prostate cancer [19], 
pancreas cancer [20] and breast cancer [21]. ALDH1-positive cells can generate tumors from 
xenotransplantation situation, thus ALDH1 might be used to describe the long-time-sought cancer stem 
cells and even cancer prognosis [22]. According to Ginestier [23], the expression of ALDH1 in tumor 
cells can disclose an earlier phase of progenitor cells. In addition, ALDH1-positive tumor cells may 
have inherited aggressive properties including ability to self-renew, high proliferation potential, and 
resistance to damaging agents. ALDH1 expression is associated with self-renewal of normal cells and 
can be a predictor of poor prognosis among cancer patients [24]. The molecular level of ALDH1 
researches can be transferred to practical utility of ALDH1 in clinical diagnosis and prognosis. 
 
The primary function of ALDH1A1 concerns with encoding a homotetramer, which are ubiquitously 
distributed in epithelium of various organs such as testis, brain, eye lens, liver, kidney, lung and retina 
[25]. Recent studies suggest that ALDH1A1 may play an important role in cancer therapeutics prognosis 
effect and mechanism [26], which may result from a decrease in effectiveness of anticancer drugs. 
Because ALDH1A1 can detoxify major active aldehyde metabolites especially in breast cancer, 
ALDH1A1 expression in the breast is associated with unfavorable clinical outcomes [21]. So breast 
cancer patients who expressed lower ALDH1A1 expression status were likely to respond to CP-based 
treatment significantly more compared to those who have higher ALDH1A1 expression level. Previous 
studies also indicated that ALDH1A1 may be a predictor of the drug’s therapeutic effectiveness among 
non-small cell lung cancer patients [27]. ALDH1A1 is not only a potential marker of cancer stem cells, 
but also involves in the formation of tumor-initiating cells in ovarian tissues [28].  Besides this, a variety 
of non-cancerous cells including hematopoietic progenitor cells can express higher ALDH1A1 levels 
[4]. Original researches also indicated ALDH1 positive status is associated with epithelial-mesenchymal 
transition, the process of which is considered to be prerogative in tumor metastases [29]. ALDH1A1 
positive cells are enriched in CSCs and are associated with progression of bladder cancer [30]. Also the 
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ALDH1A1 positive cells define invasive CSCs and ALDH1A1 predicts poor prognosis in esophageal 
squamous cell carcinoma [31]. ALDH1A1 can downregulate certain cancers and has also been shown 
to interact with certain anticancer drugs including daunorubicin and flavopiridol [32].  
 
Like ALDH1A1, the isoenzyme of ALDH1A2 also has the function of encoding a cytosolic 
homotetramer, which are expressed and exist in various embryonic tissues [33].  ALDH1A2 plays a 
crucial role in regulating RA synthesis, therefore ALDH1A2 may affect cell growth and differentiation 
as well as apoptosis, leading to an anticancer effect [4]. Previous studies indicated ALDH1A2 is a 
candidate tumor suppressor for prostate cancer [34]. ALDH1A2 may be an excellent potential target for 
individualized treatment for gastric cancer patients because ALDH1A2 demonstrates the association 
with prognosis [35]. Other studies also suggest the implication of ALDH1A2 in for non-small cell lung 
cancer [36]. Low ALDH1A2 expression is associated with unfavorable recurrence-free survival in non-
small cell lung cancer patients [37]. 
 
Expression of ALDH1A3 has been found in a variety of organs such as salivary gland [38], stomach 
[39], breast [40], kidney [41] and fetal nasal mucosa [42]. ALDH1A3 has been shown to play a critical 
role in development of human tissues. Several studies have demonstrated that ALDH1A3 deficiency 
may be correlated with prognosis of certain cancer types.  Like ALDH1A1 and ALDH1A2, ALDH1A3 
is also a cytosolic homodimer and participates in the synthesis of RA and even embryonic development 
[43].  ALDH1A3 can be expressed in various late-stage embryonic and adult rodent tissues. Negative 
ALDH1A3 expression in mouse embryos is leading such mice more likely to die from defects in nasal 
development [44]. Previous studied reported that low ALDH1A3 expression status may play a critical 
role in a variety of cancers [4]. ALDH1A3 expression has been found to be downregulated in human 
breast cancer MCF-7 cells [45] and upregulated by induction of wild type p53 in cultured human colon 
cancer cells [46]. ALDH1A3 has been proposed as a prognostic marker for nonmuscle invasive bladder 
cancer [47]. ALDH1A3 expression is methylation-silenced in gastric cancer cells [48] and can be 
induced by the antitumor agent IL-13 cytotoxin in glioblastoma cells [49], which results in different 
prognosis outcomes in those tumor cells. ALDH1A3 belongs to the five candidate genes(Aldh1a3, Chd2, 
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Nipa2, Pcsk6, and Tubgcp5) within a region related to mammary tumorigenesis [50]. In humans, 
ALDH1A3 expression may be associated with enhancing malignant behavior of certain cancer types, 
and ALDH1A3 might be a new therapeutic target for cancer treatment [51].      
         
ALDH1B1 is a mitochondrial protein expressed and exist extensively in various human tissues including 
liver, testis, kidney, skeletal muscle, heart, placenta, brain and lung [52]. Recent studies have shown 
that ALDH1B1 is involved in the metabolism of the ethanol-derived acetaldehyde and may represent a 
link between alcohol consumption and diabetes [53].  ALDH1B1 might be a crucial isozyme for colon 
cancer tumorigenesis, because ALDH1B1 can modulate related signal pathways [53]. ALDH1B1 
displays relatively high affinity for acetaldehyde and is believed to play a major role in acetaldehyde 
oxidation in vivo [54].  
 
The primary function of ALDH1L1 concerns with catalyzing the formation of tetrahydrofolate from 10-
formyltetrahydrofolate [55]. ALDH1L1 also has the function of cellular proliferation, so ALDH1L1 
might be closely associated with cancer formation and progression. The positive expression of 
ALDH1L1 in different cancer cell can result in suppressed cellular proliferation and increased 
cytotoxicity, which might be attributed to its catalytic function[56]. ALDH1L1 is significantly 
downregulated in human liver, lung, prostate, pancreas and ovarian cancers, which may enhance tumor 
proliferation [57]. There consists with two intronic SNPs in ALDH1L1 and they are associated with one 
increasing and one decreasing risk respectively for breast cancer patients, indicating potential influence 
on breast cancer [58]. What’s more, ALDH1L1 is reported to have protective role for retinal cells [59]. 
Lower retinal tetrahydrofolate levels can affect ALDH1L1 in formate oxidation because of its additional 
role of methanol toxicity [4]. ALDH1L1 may work as a good target for personal treatment among gastric 
cancer patients, and ALDH1L1 may be associated with better overall survival in breast cancer patients 
[38]. ALDH1L2 is one of the most recently found isoenzyme in ALDH superfamily and is mainly 
expressed in spleen and corpus callosum tissue [60]. According to limited researches found, breast 
cancer treatment that uses anti-inflammatory agent can upregulate ALDH1L2 expression [61]. 
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The total studies above indicate that enhanced ALDH1 expression might be a hallmark for cancer stem 
cells(CSC) [62] and cancer stem cells are believed to possess characteristics of tumorigenesis in 
particular cancer types [16]. The objective of this study was to systematically investigate the 
significance of ALDH1 genes for prognosis and clinical outcomes in cancer patients.  Hazard Ratio can 
represent instantaneous risk over the follow-up time period and can indicate risks for the cumulative 
follow-up period [63]. The survival analysis involves a series of follow-up time intervals between a 
fixed starting point and the terminating event and in this study it’s the death of cancer patient [64]. The 
calculation of Hazard Ratio differs from Relative Risk or Odds Ratio in case-control studies is that the 
time contribution of individual cancer patients vary by the time of termination and their full survival 
times remain unknown. The Kaplan-Meier survival curve and log-rank test to investigate difference 
between two groups are examples of univariate analysis method, in which survival is described with 
respect to the factor while ignoring other variables’ influence [65] . It’s more common in clinical 
researches that more than one covariates or variables will exert influence on cancer patients’ prognosis, 
including different genotypes, drug treatment, age, race or combination of these covariates. Therefore, 
it’s more desirable to adjust these covariates while investigating the cancer patients’ survival in relation 
to ALDH1 status. In previous survival analysis of cancer patients with ALDH, Hazard Ratio is the 
comparison of death or recurrence corresponding to survival in patients between ALDH-positive and 
ALDH-negative groups. The Cox Regression model [66] seeks to describe association between the 
event incidence by hazard function and a set of covariates and the hazard is the instantaneous event 
probability at a given time or the probability that an individual cancer patient under follow-up time 
period the event in a time interval centered around that point.  
 
In meta-analysis, the clinical outcomes for time-to-event survival analysis is Hazard Ratio for overall 
survival or disease-free survival. However, not all studies include individual patient data and carry out 
the Cox regression analysis for Hazard Ratio. Methods are still available to obtain HRs associated 
statistics by carefully manipulating the published data that only include Hazard Ratio or Kaplan-Meier 
curve[67]. It may be possible to extract data from published Kaplan-Meier curves by digitizing data 
from a number of time intervals on the curves and then pool across these time intervals within a trial to 
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estimate HR that can represent the entire curve. The practical method proposed by Tierney[67] for 
incorporating summary hazard ratio into meta-analysis can provide stronger analysis because excluding 
researches that didn’t calculate HR may introduce a bias and may not report the necessary statistical 
information to allow estimation of entire HRs. More often, the researches can present the outcomes in 
different ways and by different cut-off point standard.  
  
This study helps fill the gap of the efficacy and time-to-event association between candidate ALDH 
genes with various cancer types. This study provides a more comprehensive review for ALDH1 genes 
and cancer types, the result of which shed interesting light on whether ALDH1 is a good biomarker for 
cancer patient prognosis. The association of ALDH1 and clinicopathological features of cancer patients 
with corresponding prognostic outcomes remain controversial. The clinical significance of this meta-
analysis study is the implementation ALDH1 in clinical prognosis prediction broadens the research area 


















The articles for this meta-analysis study is identified by searching the PubMed, EMBASE and Web of 
Science databases. We searched English language studies that analyzed the associations between 
ALDH1 genes expression and prognosis in cancer patients. The search strategy used the clinical queries 
prognosis filter in databases mentioned above. And the key words for searching are as following: 
(Prognosis/Broad[filter])AND(ALDH1 OR ALDH1A1 OR ALDH1A2 OR ALDH1A3 OR ALDH1B1 
OR ALDH1L1 OR ALDH1L2)AND(cancer OR tumor OR neoplas* OR malignan* OR metastat* OR 
recurrence) AND(Humans[Mesh] AND English[lang]). 
 
The search results were then screened according to the following inclusion criteria:  
1) evaluation of the association between ALDH1 genes expression and overall survival(OS) or disease-
free survival(DFS) or other prognostic factors among all types of cancer patients;  
2) inclusion of validated data to calculate hazard ratio(HR) with a 95% confidence interval(95%CI) for 
Overall Survival, Disease-Free Survival, or other prognostic outcomes among cancer patients; 
3) inclusion of Kaplan-Meier survival curve to carry out data extraction and calculate unadjusted hazard 
ratio(HR) based on follow-up information; 
4) English language original researches; 
5) inclusion of original researches with sufficient sample size of more than twenty patients; 
6) articles published as original researches. Reviews were excluded.  
 
The following five criteria were implemented to assess the quality of the original researches:  
1) appropriate research design for survival analysis in cancer patients;  
2) meeting the inclusion criteria stated in the previous paragraph;  
3) clear research objectives for ALDH1 genes prognosis for different types of cancers;  
4) appropriate statistical analysis for Hazard Ratio of clinical outcomes in prognosis prediction,  
5) consideration of research bias and standardization.  
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The following information was extracted from each published researches: title, first author, publication 
year, key words, number of patients, histopathological cancer type, analysis method applied, cutoff 
value of ALDH1 expression, Hazard Ratio, 95%CI for HR, p-value, Kaplan-Meier curve. The original 
researches for screening and reviewing were before February 29, 2016.  
 
Definitions and Standardizations 
This study used a priori defined standardized outcomes and definitions for ALDH1 status to avoid 
subjective selection of outcomes and definitions across studies as much as possible. Expression of 
ALDH1 is measured by immunohistochemistry as part of the large gene analysis. For 
immunohistochemistry, we define ALDH1-positive status as nuclear staining in tumor cells or at least 
moderate staining in qualitative scales. The cut-off point may vary across included publications. If 
different ALDH1-positive status were used, the cut-off point is recorded according the original papers. 
The comparison groups for Hazard Ratio or Relative Risk in the survival analysis were transformed and 
standardized to ALDH1-positive group vs. ALDH1-negative group, with negative expression as the 
reference. The main outcome was Hazard Ratio for Overall Survival or Disease-Free Survival by Cox 
Regression Analysis. To avoid bias that may arise, if investigators select the follow-up period to report 
according to the results at each follow-up interval, we standardized definitions to include 24 months of 
follow-up in all studies. Cox models that allow estimation of a hazard ratio for the entire follow-up 
survival analysis are not routinely presented in ALDH1 studies.  
 
Data Extraction      
For each individual research, we recorded author name, journal and year of publication, sample size, 
cancer type, demographics, gene and ALDH1 status for immunohistochemistry analyses, definition of 
a ALDH1- positive status, cox model analysis used, outcome, HR, 95%CI, p-value during the analysis, 
overall survival, disease-free survival. For papers didn’t include Hazard Ratio, we used Kaplan-Meier 
survival curve and methods based on Tierney to calculate the Hazard Ratio for the study. The 
PlotDigitizer was used to extract the data from Kaplan-Meier curve. According to Tierney[67], the 
Hazard Ratio can be calculated in each time interval and two groups. The data taken into calculation 
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include following steps:1) event-free at the start of the interval, 2) censored during the interval, 3) at 
risk during the interval, 4) the number of events during each time interval, 5) O-E, V and HR for each 
time interval, 6) O-E, V and HR for the entire Kaplan-Meier curve. PlotDigitizer can extract data for 
numbers event-free at the start of specific time interval for ALDH1-positive group and ALDH1-negative 




To determine poor clinical outcome associated with each category of ALDH1 genes and cancer types, 
hazard ratio (HR) from time-to-event analyses was extracted along with the 95% confidence interval as 
well as ALDH1 expression level. When the 95% confidence interval was not available from original 
papers, two methods were used to validate the data of such studies. 95%CI can be calculated by HR and 
p-value, or 95%CI can be approximated from Kaplan-Meier curve. The association of the expression 
of ALDH1 and the general prognostic markers is assessed for breast cancer, colon cancer, esophageal 
squamous cell, head and neck squamous carcinoma, non-small cell lung cancer, ovarian cancer and 
rectal cancer, and the survival outcomes including overall survival, disease-free survival or other 
prognosis outcomes. The published data and figures from original papers were used to assess the HR 
according to the methods described by Parmar et al[68]. Adjusted Hazard Ratio was calculated by 
multivariate analysis based on Cox Regression Model, and unadjusted Hazard Ratio was calculated by 
univariate analysis. The Hazard Ratio calculated from Kaplan-Meier curve was unadjusted Hazard 
Ratio. Both adjusted and unadjusted Hazard Ratio were included in this meta-analysis and were 
categorized into different subgroups. The original research articles that meet the inclusion criteria of 
this meta-analysis should be included, even if unadjusted Hazard Ratio for such articles needs to be 
calculated from Kaplan-Meier curve. To exclude such articles may introduce bias for this meta-analysis. 
Forest plots of Hazard Ratios of survival analysis were constructed to show the association between 
ALDH1 gene expression and overall survival or disease-free survival, the outcomes of which were end 
points in this meta-analysis. The p-values for Hazard Ratios were two-sided, with the significance cut-
off point setting at smaller than 0.05.   
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The heterogeneity assumption was calculated by using a Q-test, and P-values greater than 0.05 indicated 
a lack of heterogeneity among studies. Hence the differences for subgroup studies were due to chance 
and fixed-effect model was used. Otherwise, a random-effect model (DerSimonian-Laird method) was 
used. I2 was chosen as the indicator for subgroup heterogeneity study and the cutoff standard for 
choosing fixed-effect model or random-effect model was based on whether I2>50% and whether p>0.05. 
In addition, in order to see whether individual studies will influence on the pooled effect, a sensitivity 
analysis was performed. The sensitivity analysis sequentially excluded each individual study in each 
meta-analysis and examined whether the pooled HRs were significantly changed. Funnel plots and 
Egger’s test were constructed to estimate the possible evidence for publication bias. The funnel plots 
included each individual studies with each point positioning in different X-axis(Hazard Ratio of the 
study) and Y-axis(standard error of LogHR). The expected findings of smaller studies will distribute 
randomly centered around the pooled Hazard ratio. And in comparison, larger studies will show tighter 
cluster around the pooled Hazard Ratio. If there’s publication bias, the funnel plots will show an 
asymmetric distribution. If no significant publication bias exists, all the studies will show a symmetric 
triangular funnel on funnel plots. All statistics are processed by Review Manager 5.3(The Nordic 
Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). Generic Inverse Variance 















Figure 1. Flow diagram showing the inclusion and exclusion of studies on ALDH1 genes and all possible cancer prognosis.  
 
Figure 1 and Table 1 show the flow of inclusion and exclusion process of studies on ALDH1 genes and 
all possible cancer patients’ prognosis. A total number of one hundred and twenty one papers met the 
inclusion criteria for this meta-analysis after screening abstracts and reviewing original papers. Four 
thousand three hundred and fifty four papers were identified from PubMed, EMBASE or Web of 
Science database. After excluding duplicated papers, one thousand and twenty three papers were 
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screened for abstract. Three hundred and seventy seven papers were excluded based on screening result, 
because such studies were cellular mechanism study rather than patients survival analysis. Seven 
hundred and forty five papers were fully read and five hundred and fifty six full-text papers were 
excluded. The exclusion reasons include: thirteen papers were animal studies with no population data, 
one hundred and eighty three papers were cancer stem cell studies, one hundred and ninety-six papers 
lacked follow-up information and only reported gene expression of ALDH1 genes, forty-four papers 
were reviews, and twenty one papers were published in other languages. Among the remaining one 
hundred and eighty nine eligible papers for systematic review, sixty-eight papers were excluded from 
meta-analysis. The reasons include same study cohorts across researches, insufficient sample size (<20), 
inadequate data for Hazard Ratio calculation and only reported p-value, logically inconsistent Hazard 
Ratio. In the end, a total number of one hundred and twenty one original researches were eligible for 
this meta-analysis.  
 
Table 1.  Flow table showing number of inclusion and exclusion of this meta-analysis studies. 
 ALDH1 ALDH1A1 ALDH1A2 ALDH1A3 ALDH1B1 ALDH1L1 ALDH1L2 
Total published paper 
(PubMed, EMBase and Web 
of Science) 
3064 860 111 186 63 60 10 
Remaining papers after 
excluding duplicates 595 252 48 68 22 28 10 
Remaining papers after 
screening (abstract only) 396 241 33 46 10 19 0 
Remaining papers after full-
text review 111 51 5 13 1 8 0 
Number of unique papers 
for each category (after 
excluding the ones with 
insufficient data)  
68 40 5 10 1 4 0 
Total number of unique 
papers for the meta-analysis 121 
 
 
Table 2.1 Eligible studies for ALDH1 on cancer prognosis (not specifying the ALDH1 family). First author, cancer type, patient size, cut-off 
point for ALDH expression, analysis method and outcomes are recorded. 
First author Cancer type 
Patient 
Number gene 




Liu[25] astrocytoma 76 ALDH1 0 adjusted OS, DFS 
Goudarzi[69] astrocytoma 36 ALDH1 0 unadjusted CS 
Ito[70] axillary lymph node metastases 47 ALDH1 0 adjusted DFS 
Xu[71] bladder cancer 227 ALDH1 0 adjusted OS, DFS 
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Mieog[72] breast cancer 193 ALDH1 0 adjusted OS, DFS 
Mieog[72] breast cancer 61 ALDH1 0 unadjusted OS, DFS 
Yasuyo[73]** breast cancer 257 ALDH1 0 adjusted OS, DFS 
Yasuyo[73]** breast cancer 106 ALDH1 0 adjusted DFS 
Charafe-
Jauffret[74] breast cancer 77 ALDH1 0 adjusted MFS, SS 
Sakakibara[75] breast cancer 115 ALDH1 0 adjusted OS 
Tan[76]* breast cancer 139 ALDH1 0 unadjusted DFS 
Zhong[77] breast cancer 121 ALDH1 0 adjusted DFS 
Genestier[28] breast cancer 577 ALDH1 0 adjusted OS 
Kang[78]* breast cancer 390 ALDH1 0 unadjusted OS, DFS 
Bane[79]* breast cancer 255 ALDH1 NA unadjusted OS 
Ito[73]** breast cancer 47 ALDH1 0 adjusted DFS 
Zheng[80] breast cancer 65 ALDH1 0 adjusted OS 
Nogami[81] breast cancer 40 ALDH1 0 unadjusted DFS 
Neumeister[82] breast cancer 642 ALDH1 NA adjusted OS 
Huang[83] breast cancer 552 ALDH1 0 unadjusted DFS 
Zhou[84] breast cancer 61 ALDH1 0 adjusted OS 
Yu[85]* breast cancer 96 ALDH1 0 unadjusted DFS 
Morimoto[86] breast cancer 203 ALDH1 0 adjusted OS 
Bednarz-Knoll[87] breast cancer 330 ALDH1 0 adjusted OS, DFS 
Dong[88] breast cancer 161 ALDH1 0 adjusted OS, DFS 
Kim[89] breast cancer 227 ALDH1 0 unadjusted OS 
Brot[90] breast cancer 140 ALDH1 0 adjusted OS 
Hashimoto[91]* breast cancer 92 ALDH1 0 unadjusted OS, DFS 
Lee[92] breast cancer 184 ALDH1 0 adjusted DFS 
Santilli[93] breast cancer 110 ALDH1 NA adjusted MFS, SS 
Pistelli[94] breast cancer 81 ALDH1 0 unadjusted OS 
Yao[95] cervical cancer 198 ALDH1 0 adjusted CS 
Xie[96] cervical cancer 52 ALDH1 0 adjusted OS, DFS 
Hou[97] cervical cancer 179 ALDH1 NA adjusted OS, DFS 
Goossens-
Beumer[98] colon cancer 232 ALDH1 NA adjusted OS, DFS, DSS 
Zhou[99]* colon cancer 60 ALDH1 20% unadjusted CS 
O'Dwyer[100] colon cancer 28 ALDH1 0 unadjusted CS 
Vogler[101] colon cancer 60 ALDH1 0 adjusted OS 
Rahadiani[102] endometrioid adenocarcinoma 98 ALDH1 0 adjusted OS, DFS 
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Honing[102] esophageal squamous cancer 94 ALDH1 NA unadjusted OS, DFS 
Minato[103]** esophageal squamous cancer 56 ALDH1 0 adjusted DFS 
Minato[103]** esophageal squamous cancer 40 ALDH1 0 adjusted DFS 
Minato[103]** esophageal squamous cancer 56 ALDH1 0 adjusted DFS 
Wang[104] esophageal squamous cancer 79 ALDH1 0 adjusted OS 
Hwang[105]* esophageal squamous cancer 41 ALDH1 0% unadjusted CS 
Ji[106] esophageal squamous cancer 138 ALDH1 NA adjusted OS 
Ajani[107] esophageal squamous cancer 167 ALDH1 0 unadjusted OS, DFS 
Kim[108] 
Eyelid Sebaceous Gland 
Carcinoma 50 ALDH1 NA adjusted MFS, SS 
Suzuki[109] liver cancer 49 ALDH1 NA unadjusted DFS 
Morise[110] lung cancer 105 ALDH1 0 adjusted OS, DFS 
Okudela[111] lung cancer 177 ALDH1 85% adjusted DFS 
Zenke[112] lung cancer 52 ALDH1 NA adjusted DFS 
Liu[113] oral cancer 141 ALDH1 0 adjusted OS 
Ayub[114] ovarian cancer 55 ALDH1 0 adjusted OS, DFS 
Liebscher[115] ovarian cancer 112 ALDH1 0 adjusted OS 
Kuroda[116]* ovarian cancer 123 ALDH1 0 unadjusted DFS 
Chen[117] ovarian cancer 80 ALDH1 0 adjusted OS 
Mizuno[118]* ovarian cancer 81 ALDH1 10% adjusted OS 
Huang[119] ovarian cancer 232 ALDH1 NA adjusted OS 
Wang[120] ovarian cancer 84 ALDH1 50% adjusted OS 
Chang[121]* ovarian cancer 442 ALDH1 20% adjusted OS 
Avoranta[122] rectal cancer 197 ALDH1 0 adjusted DFS 
Seung[123] rectal cancer 51 ALDH1 NA adjusted OS, DFS 
Deng[124]* rectal cancer 64 ALDH1 21% unadjusted DFS 
Yoon[125] rectal cancer 145 ALDH1 0 adjusted DFS, CSS 
Goossens-
Beumer[101]** rectum cancer 73 ALDH1 NA adjusted OS, DFS, DSS 
Liu[126] renal pelvis carcinoma 114 ALDH1 0 unadjusted OS, DFS 
Huang[127] 
tongue squamous cell 
carcinoma 66 ALDH1 >1 unadjusted OS 
Kitamura[128] urinary cancer 226 ALDH1 0 adjusted CSS 
Wu[129]* volvar squamous cancer 154 ALDH1 0 unadjusted DFS 
NA: not applicable 
*: The Hazard Ratio of these articles were calculated from Kaplan-Meier curve. 








Table 2.2: Eligible studies for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1 and ALDH1L1 on cancer prognosis.  First author, cancer type, 
patient size, cut-off point for ALDH expression, analysis method and outcomes are recorded. 
First author Cancer type Patient Number Gene 




Su[30]* bladder cancer 216 ALDH1A1 NA unadjusted OS 
Khoury[130] breast cancer 513 ALDH1A1 NA adjusted OS, DFS 
Liu[131] breast cancer 596 ALDH1A1 0 adjusted OS, DFS 
Wei[132] breast cancer 92 ALDH1A1 NA adjusted OS, DFS 
Ali[133] breast cancer 2392 ALDH1A1 4 adjusted OS 
Wu[134] breast cancer 3455 ALDH1A1 NA unadjusted OS 
Zhong[134] breast cancer 147 ALDH1A1 0 adjusted DFS 
Zhou[135] breast cancer 119 ALDH1A1 10% adjusted OS 
Sjöström[136] breast cancer 426 ALDH1A1 10% adjusted DFS 
Kahlert[137] 
colon and rectal 
cancer 996 ALDH1A1 NS unadjusted OS, DFS 




carcinoma 134 ALDH1A1 NA unadjusted OS 
Li[139] gastric cancer 216 ALDH1A1 0 adjusted OS, DFS 
Shen[35] gastric canceer 876 ALDH1A1 0 unadjusted OS 
Adam[140] glioblastoma 93 ALDH1A1 0 adjusted OS 
Xu[141] glioma 237 ALDH1A1 5 adjusted OS 
Qian[142] HNSCC 81 ALDH1A1 0 adjusted DFS 
Koukourakis[143] HNSCC 74 ALDH1A1 5% adjusted DFS 
Xu[144]* HNSCC 96 ALDH1A1 1.3 unadjusted OS, DFS 
Leinung[145]* HNSCC 48 ALDH1A1 0 unadjusted OS 
Martin[146] larygeal cancer 84 ALDH1A1 0% adjusted DFS 
Tanaka[147] liver cancer 60 ALDH1A1 >1 adjusted DFS 
Jiang[148] lung cancer 303 ALDH1A1 10% unadjusted OS 
Li[149] lung cancer 179 ALDH1A1 0 adjusted OS 
Sullivan[150] lung cancer 282 ALDH1A1 NA unadjusted OS 
Shimada[151] lung cancer 103 ALDH1A1 5% adjusted OS 
Dimou[152]** lung cancer 
134 
ALDH1A1 
0 unadjusted DFS 
296 0 unadjusted DFS 
You[36]** lung cancer 1926 ALDH1A1 NA unadjusted OS 
Alamgeer[153] lung cancer 205 ALDH1A1 NA adjusted OS, DFS 
Gao[154] lung cancer 133 ALDH1A1 0 adjusted OS 
Kaminagakura[155]** 
oral squamous cell 
carcinoma 100 ALDH1A1 10% unadjusted DFS 
Ishiguro[156] ovarian cancer 90 ALDH1A1 NA unadjusted OS, DFS 
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Chui[157] ovarian cancer 558 ALDH1A1 0 unadjusted OS 
Kahlert[158] pancreatic cancer 97 ALDH1A1 4 adjusted OS 
Xing[159] 
papillary thyroid 
carcinoma 247 ALDH1A1 NA adjusted DFS 
Li[160] prostate cancer 163 ALDH1A1 10% adjusted OS, CSS 
Magnen[161]* prostate cancer 85 ALDH1A1 NA unadjusted OS 
Sung[162]* 
pulmonary 
adenocarcinoma 97 ALDH1A1 NA unadjusted OS, DFS 
Wang[163] renal cancer 95 ALDH1A1 NA unadjusted OS, DFS 
Aguilera[164]* 
Sporadic colorectal 
cancer 699 ALDH1A1 0 unadjusted OS 
Wu[138]** breast cancer 3455 ALDH1A2 NA unadjusted OS 
Shen[35] gastric canceer 876 ALDH1A2 0 unadjusted OS 
Seidensaal[165] HNSCC 101 ALDH1A2 NA adjusted OS, DFS 
You[38]** 
non-small cell lung 
cancer 1926 ALDH1A2 NA unadjusted OS 
Kostareli[166]* 
oropharyngeal 
squamous cancer 115 ALDH1A2 NA unadjusted OS, DFS 
Kim[47]* bladder cancer 163 ALDH1A3 0% adjusted DFS 
Marcato[167] breast cancer 176 ALDH1A3 NA adjusted OS 
Jiang[168] breast cancer 144 ALDH1A3 0% adjusted OS 
Liu[131] breast cancer 596 ALDH1A3 0 adjusted OS, DFS 
Wu[138] breast cancer 3455 ALDH1A3 NA unadjusted OS 
Qiu[169]* breast cancer 125 ALDH1A3 0 unadjusted OS 




NA unadjusted OS 
443 NA unadjusted OS 
You[38]** 
non-small cell lung 
cancer 1926 ALDH1A3 NA unadjusted OS 
Casanova-Salas[171] prostate cancer 
46 
ALDH1A3 
0 adjusted OS 
80 0 adjusted OS 
You[38]** lung 1926 ALDH1B1 NA unadjusted OS 
Wu[138]** breast cancer 3455 ALDH1L1 NA unadjusted OS 
Shen[37]** gastric canceer 876 ALDH1L1 0 unadjusted OS 
Chen[172] liver cancer 112 ALDH1L1 0 adjusted OS 
You[38]** lung 1926 ALDH1L1 NA unadjusted OS 
NA: not applicable 
*: The Hazard Ratio of these articles were calculated from Kaplan-Meier curve. 





Table 2.1 listed the characteristics of eligible studies to examine association of ALDH1 genes and cancer 
prognosis. Sixty eight papers were eligible and it covers nineteen different cancer types. This sixty eight 
papers didn’t specify the ALDH1 genes. Through the inclusion flow process, we can find the majority 
of original researches didn’t specify ALDH1 genes isozymes. This might be due to the limitation of 
experiment design, the budget for identifying gene marker. Some paper incorporated ALDH1 as 
ALDH1A1, perhaps ALDH1A1 was the main and largest gene type for ALDH1 genes. However, in this 
meta-analysis, we separate the original researches of ALDH1 as a specific subgroup. Table 2.2 listed 
the characteristics of eligible studies for ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, and 
ADLH1L1. Forty papers were available for ALDH1A1 and prognosis studies and they covered eighteen 
cancer types. Five papers examined prognosis effect of ALDH1A2 and five different cancers. Ten 
papers targeted on ALDH1A3 and six cancer types were studied. Only one paper was available for 
ALDH1B1. Four papers studied ALDH1L1 and four cancer types. Two papers [38, 139] categorized 
ALDH1 genes into each specific subgroups, thus records were repeated for available study number and 
patient number included. 
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Figure 2.1 Association between ALDH1 genes and Overall Survival for breast cancer 
 
Figure 2.1 shows the results of the meta-analysis of ALDH1, ALDH1A1, ALDH1A3 expression in 
prognosis of overall survival in breast cancer patients, for which sixteen papers were available for 
association with ALDH1, six papers were available for association with ALDH1A1 and five papers were 
available for association with ALDH1A3. A total number of 11,983 breast cancer patients were 
identified by three ALDH1 genes and were evaluated for overall survival as a clinical outcome. The 
pooled hazard ratio for overall survival using Random Effect Model between ALDH1 genes positive 
patients and ALDH1 genes negative patients is 1.83, with 95%CI of (1.46, 2.28), which suggested 
ALDH1 genes were a significant poor prognosis predictor for overall survival in breast cancer 
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patients(p<0.001). ALDH1 genes show different prognosis effect when the HR is calculated by 
multivariate analysis of Cox Regression model with controlling covariates and univariate analysis 
without controlling covariates, because adjusted HRs are less biased. The Hazard Ratio for adjusted 
Overall Survival is 2.52(95%CI: 1.77, 3.60) between breast cancer patients with ALDH1 positive 
expression and breast cancer patients with ALDH1 negative expression (p<0.001). In comparison, the 
Hazard Ratio for unadjusted Overall Survival falls to 0.98(95%CI: 0.57, 1.67) between the ALDH1 
positive and negative caner patients. Similarly, the Hazard Ratio for adjusted Overall Survival is 
2.65(95%CI: 0.98, 7.12) for breast cancer patients ALDH1A1 positive expression compared to patients 
with negative expression. For ALDH1A3, the Hazard Ratio for multivariate Overall Survival is 
1.75(95%CI: 1.02, 2.97) for breast cancer patients with positive expression versus patients with negative 
expression. The Hazard Ratio falls to 1.09(95%CI: 0.97, 1.22) for univariate Overall Survival for breast 
cancer patients with positive ALDH1A3 expression and negative ALDH1A3 expression. The I2 of 
Heterogeneity analysis indicated the overall studies and subgroup studies have significant heterogeneity 
for the association between ALDH1 genes and breast cancer overall survival (I2>50%, p<0.05), thus 
random-effect model is applied for this meta-analysis. This forest plot indicated that Overall Survival 
with adjusted HR of ALDH1 genes predicts a significant poor prognosis for breast cancer patients, while 
Overall Survival with unadjusted HR may not be a significant prognosis predictor for breast cancer 
patients. In sensitivity analysis, each study was sequentially excluded to examine if change in the pooled 
Hazard Ratio was significant. No significant change was found for meta-analysis between ALDH1 




Figure 2.2. Association between ALDH1 genes and Disease-Free Survival in Breast Cancer 
 
Figure 2.3 Association between ALDH1 genes and Disease-Free Survival in Breast Cancer after sensitivity analysis. 
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Figure 2.2 is the forest plot of indicating expression of ALDH1, ALDH1A1, ALDH1A3 in prognosis of 
disease-free survival (DFS) in breast cancer patients, for which twenty papers were included for this 
analysis. A total number of 4,073 breast cancer patients were identified by ALDH1, ALDH1A1 and 
ALDH1A3 in subgroup analysis. The pooled Hazard Ratio for disease-free survival between breast 
cancer patients with ALDH1 genes positive expression and patients with negative expression is 2.15 
with 95%CI of (1.45, 3.18) and the poor prognosis for disease-free survival is significant (p<0.001). 
For the ALDH1 genes subgroup, the hazard ratio for adjusted DFS is 2.00(1.24, 3.23) in breast cancer 
patients with positive ALDH1 expression versus patients with negative expression. The hazard ratio for 
DFS in breast cancer patients was 2.28(0.58, 8.94) when the multivariate analysis is switched to 
univariate analysis. The adjusted HR for DFS is 2.02(0.86, 4.74) for breast cancer patients with positive 
ALDH1A1 expression in comparison to patients with negative ALDH1A1 expression. Based on the 
heterogeneity results, the subgroup for ALDH1 and unadjusted DFS in breast cancer patients showed 
insignificant heterogeneity (I2<50, p=0.11). But the pooled HR analysis and other subgroups show 
significant heterogeneity (I2>50, p<0.05). So random-effect model is used for meta-analysis between 
ALDH1 genes and prognosis of disease-free survival in breast cancer patients. This forest plot indicated 
that adjusted Disease-Free Survival of ALDH1 genes predicts a significant poor prognosis for breast 
cancer patients, while unadjusted Disease-Free Survival may not be a significant prognosis predictor 
for breast cancer patients. In Mieog’s study [69], patients were categorized into two groups based on 
their age (.>65ys) and the disease-free survival were conducted respectively in these two cohorts. When 
conducting sensitivity analysis for this meta-analysis, we found research by Charafe-Jauffret [71] for 
association of ALDH1 and adjusted DFS among breast cancer patients exerted significant changes for 
the pooled Hazard Ratio. This original research concluded by Kaplan Meier univariate analysis for 
metastasis free survival of 74 inflammatory breast carcinomas, without controlling the covariates that 
may contribute to disease-free survival. After deleting the result of this study, the pooled unadjusted 
Hazard Ratio of disease-free survival related to ALDH1 genes among breast cancer patients falls to 1.28 
(95%CI: 0.83, 1.96). The overall Hazard Ratio of disease-free survival is 1.61 (95%CI: 1.26, 2.06) 
between breast cancer patients who expressed ALDH1 genes and who didn’t, as showed in Figure 2.3 
after conducting sensitivity analysis.  
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Figure 3. Association between ALDH1 genes and Overall Survival in Colon Cancer 
Figure 3 is the forest plot to show the association of ALDH1 genes expression and prognosis of overall 
survival in colon cancer patients. Six studies were included into this meta-analysis and a total number 
of 2,135 colon cancer patients were followed up for overall survival analysis. The pooled Hazard Ratio 
for Overall Survival in Colon Cancer between patients with positive expression of ALDH1 genes and 
patients with negative expression of ALDH1 genes is 2.13(95%CI: 0.97, 4.66) and HR of OS is 
significant predictor for poor prognosis. The adjusted Hazard Ratio of overall survival in colon cancer 
patients with positive ALDH1 expression is 6.50(95%CI: 3.17, 13.33) in comparison to colon cancer 
patients with negative ALDH1 expression. This Hazard Ratio calculated by Cox Regression Model is 
significant (p<0.001). The unadjusted Hazard Ratio for Overall Survival in colon cancer patients with 
positive ALDH1 gene is 0.78(95%CI: 0.29, 2.11) in comparison to patients with negative ALDH1 
expression and this unadjusted HR is not significant (p=0.631). The adjusted Hazard Ratio for Overall 
survival in colon cancer patients with positive ALDH1A1 expression is 2.11(95%CI: 1.32, 3.38) versus 
patients with negative ALDH1A1 expression. And the unadjusted Hazard Ratio for Overall Survival 
between positive ALDH1A1 expression patients and negative expression patients is 2.44(95%CI: 1.29, 
4.61). For ALDH1A1 subgroups, only one paper was included specifically for each of the two subgroups. 
The test for subgroup differences indicated the heterogeneity was significant among the papers in 
24 
different subgroups (I2>50%, p=0.006). Random-effect model was conducted in this meta-analysis to 
examine association between ALDH1 genes and Overall Survival in Colon Cancer. This forest plot 
indicated that ALDH1 genes for adjusted Overall Survival among colon cancer patients predict a 
significant poor prognosis, while ALDH1 genes may not be a significant prognosis predictor for colon 
cancer patients with unadjusted Overall Survival. In the sensitivity analysis, the original researches from 
Goossens-Beumer [95] and Zhou [96] would change the pooled Hazard Ratio significantly. But based 
on the limited availability of researches on colon cancer prognosis, more investigation was required for 
prognosis effect. The cut-off points in these two studies were 50% and 20% respectively, which means 
after standardizing expression cut-off points, the hazard ratio can be larger than this estimation. 
 
 
Figure 4.1 Association between ALDH1 genes and Overall Survival in Esophageal Squamous Carcinoma 
 
 
Figure 4.2 Association between ALDH1 genes and Disease-Free Survival in Esophageal Squamous Carcinoma 
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Figure 4.1 and Figure 4.2 are the forest plots that examine association between ALDH1 genes and 
Overall Survival as well as Disease-Free Survival among patients with Esophageal Squamous 
Carcinoma. Six papers were available for overall survival meta-analysis for esophageal squamous 
carcinoma and a total number of 652 patients were followed up for overall survival. The pooled Hazard 
Ratio of overall survival is 1.22 (95%CI: 0.82, 1.81) between esophageal squamous carcinoma patients 
who had positive ALDH1 gene expression and who had negative ALDH1 gene expression. This poor 
prognosis prediction of overall survival is not significant (p=0.33). The heterogeneity among papers for 
overall survival analysis is significant (I2>50%, p=0.03), thus random-effect model was implemented 
in this analysis. For subgroup differences test, the heterogeneity among papers that reported overall 
survival using Cox Regression Model is not significant (I2<50%, p=0.61) and heterogeneity among 
papers that reported univariate overall survival is significant(I2>50%, p=0.02). The pooled adjusted 
Hazard Ratio of overall survival is 1.49 (95%CI: 1.07, 2.08) between esophageal squamous carcinoma 
patients who had positive ALDH1 expression and who had negative ALDH1 expression. The poor 
prognosis prediction of ALDH1 for adjusted overall survival is significant (p=0.02), however only two 
papers were analyzed for this prognosis. The pooled unadjusted Hazard Ratio of overall survival is 
1.14(95%CI: 0.61, 2.13) for esophageal squamous carcinoma between patients with positive ALDH1 
and patients with negative ALDH1 expression. Four papers and 260 patients were included and the 
association is not significant (p=0.74). Based on such findings, it’s ideal for original researches to carry 
out multivariate analysis for adjusted Hazard Ratio to evaluate the association between ALDH1 genes 
and prognosis for cancer patients. The sensitivity analysis didn’t find any individual research would 
significantly alter the pooled Hazard Ratio. 
 
Three papers and 412 esophageal squamous carcinoma patients were included for meta-analysis of 
association of ALDH1 expression and disease-free survival prognosis. The heterogeneity is significant 
in this meta-analysis (I2>50%, p<0.001) and significant for both subgroup analysis (p<0.001), thus 
random-effect model was used for pooled Hazard Ratio analysis. The pooled Hazard Ratio for disease-
free survival including adjusted HR and unadjusted HR for esophageal squamous carcinoma is 1.84 
(95%CI: 0.70, 4.84) between patients with positive ALDH1 expression and patients with negative 
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ALDH1 expression. From the pooled HR, ALDH1 did not predict a significant poor prognosis for 
recurrence of esophageal squamous carcinoma (p=0.64). The adjusted disease-free survival of 
esophageal cancer patients included three different cohorts from one paper included surgery without 
induction therapy group (OP), surgery with neoadjuvant chemotherapy group (NAC) and initial 
systemic chemotherapy group (CT).  In the OP and NAC groups, multivariate analysis found that 
ALDH1 was independently associated with postoperative recurrence and prognosis (OP group, P = 
0.004 and 0.016, respectively; NAC group, P = 0.026 and 0.014, respectively).  Among the ALDH1-
negative clinical stage II/III patients, the OP and NAC groups displayed better prognoses than the CT 
group (P<0.001). However, among the ALDH1-positive clinical stage II/III patients, the OP and NAC 
groups displayed poorer prognoses than the CT group (P = 0.049). For the unadjusted disease-free 
survival analysis, two papers indicated two different prognosis effect, a significant poor prognosis with 
Hazard Ratio 3.87 (95%CI: 1.47, 10.16) and a significant good prognosis with Hazard Ratio 0.55 
(95%CI: 0.34, 0.89). The patients who showed poor prognosis of disease-free survival with esophageal 
squamous carcinoma underwent preoperative chemoradiation, so the different prognosis effects might 
be due to the diversified treatment for patients. The treatment patients received can be an important 
covariate that will influence the hazard ratio if not controlled by Cox Regression Model. Based on the 
limited researches found for disease free survival of esophageal squamous carcinoma patients and 




Figure 5. Association between ALDH1 genes and Disease-Free Survival in Head and Neck Squamous Cell Carcinoma 
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Five papers were included for meta-analysis of association between ALDH1 genes expression and 
disease-free survival in Head and Neck Squamous Cell Carcinoma(HNSCC). A total number of 388 
HNSCC patients were included in this association analysis. The pooled Hazard Ratio for disease-free 
survival in HNSCC patients with positive ALDH1 genes expression is 1.04(95%CI: 0.55, 1.96) in 
comparison to patients with negative expression. The Hazard Ratio for disease-free survival included 
both adjusted HR and unadjusted HR [143]. The heterogeneity of the five papers is significant (I2>50%, 
p=0.05), indicating more investigation should be conducted to examine the association of ALDH1 genes 
expression and HNSCC prognosis.. The pooled HR didn’t show that ALDH1 genes are significant poor 
prognosis of disease-free survival among HNSCC patients. This meta-analysis didn’t separate 
univariate disease-free survival and multivariate disease-free survival as subgroups based on papers 
identified. Based on the limited availability of researches found and the subgroups analysis, sensitivity 
analysis was not conducted in this meta-analysis. 
 
Figure6.1  Association between ALDH1 genes and Overall Survival in Non-Small Cell Lung Cancer 
 
Figure 6.1 is the forest plot to show the association of ALDH1 genes expression and overall survival in 
non-small cell lung cancer(NSCLC) patients. Seven papers were included into this meta-analysis and a 
total number of 2995 NSCLC patients were followed up for overall survival. The pooled Hazard Ratio 
for Overall Survival is 1.94 (95%CI: 1.23, 3.07) between NSCLC patients with positive ALDH1 genes 
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expression versus patients with negative ALDH1 genes expression, and the prediction for poor 
prognosis is significant (p=0.004). The heterogeneity result indicated a significant heterogeneity for 
subgroup differences (I2>50%, p<0.01), with the heterogeneity in subgroup of ALDH1A1 and adjusted 
OS not significant (I2=0%, p=0.50), heterogeneity in subgroup of ALDH1A1 and unadjusted OS 
significant (I2>50%, p<0.01). Random-effect model is conducted for this meta-analysis in ALDH1 
genes and OS in NSCLC patients. The adjusted Hazard Ratio by multivariate analysis of overall survival 
in NSCLC is 2.74 (95%CI: 2.03, 3.69) between patients with positive ALDH1A1 expression and patients 
with negative ALDH1A1 expression (p<0.001). The unadjusted Hazard Ratio by univariate analysis of 
overall survival in NSCLC is 1.18(95%CI: 1.23, 3.07) between patients with positive ALDH1A1 
expression and patients with negative ALDH1A1 expression (p=0.45). The difference in prediction of 
NSCLC overall survival can be attributed to other covariates that may contribute to this association. 
Based on sensitivity analysis, no individual researches significantly altered the pooled Hazard Ratio. 
 
Figure 6.2 Association between ALDH1 genes and Disease-Free Survival in Non-Small Cell Lung Cancer 
 
Figure 6.2 is the forest plot to show the association of ALDH1 genes expression and disease-free 
survival prognosis among NSCLC patients. Five papers were included in this meta-analysis and a total 
of 937 patients were followed-up for disease-free survival analysis. This meta-analysis was categorized 
into two subgroups, association of ALDH1 genes and adjusted Disease-free survival in NSCLC and 
association of ALDH1A1 expression and adjusted DFS in NSCLC. The pooled Hazard Ratio of disease-
free survival is 1.32(95%CI: 0.65, 2.66) for NSCLC patients with positive ALDH1 genes expression in 
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comparison to NSCLC patients with negative ALDH1 expression. This pooled Hazard Ratio is not 
significant and the pooled Hazard Ratio between the two subgroups indicated different prognosis effects. 
The Hazard Ratio for disease-free survival in NSCLC patients by Cox Regression Model is 2.50(95%CI: 
1.51, 4.12) between patients who expressed ALDH1 and patients who didn’t express ALDH1. The 
association is significant (p<0.001) and heterogeneity is not significant (p=0.81). The Hazard Ratio for 
disease-free survival in NSCLC patients by Cox Regression Model is 0.75(95%CI: 0.28, 1.97) between 
patients who expressed ALDH1A1 and patients who didn’t express ALDH1A1. This prognosis 
association is insignificant (p=0.55) and heterogeneity is significant (p<0.001). Random-Effect model 
is used to conduct this meta-analysis. The sensitivity analysis didn’t find significant change of 
individual research on pooled Hazard Ratio. The original research by Dimou [151] included two cohort 
of Yale cohort and Sotirial/Patras cohort, and followed-up the cohort separately and provided two 
hazard ratio for disease-free survival for NSCLC. To sum up, ALDH1 might be a poor prognosis for 
disease-free survival among patients suffering non-small cell lung cancer. 
 
 
Figure 7. Association between ALDH1 genes and OS prognosis in ovarian cancer 
 
Figure 7 is the forest plot to examine association between ALDH1 genes expression and overall survival 
prognosis in ovarian cancer. Nine papers and a total of 1,257 ovarian cancer patients were included for 
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this overall survival meta-analysis. Random-effect model was used because the heterogeneity is 
significant for subgroups (p<0.05). The pooled Hazard Ratio for overall survival of ovarian cancer is 
1.48 (95%CI: 1.12, 1.96) between patients who expressed ALDH1 genes and who didn’t ALDH1 genes 
and the overall survival prognosis is significant (p<0.001). For patients who expressed ALDH1 genes 
and who didn’t express, the hazard ratio for overall survival is 1.68 (95%CI: 1.02, 2.76) and the 
association is significant (p=0.04). The unadjusted Hazard Ratios for overall survival of ovarian cancer 
between patients who expressed ALDH1 and who didn’t, between patients who expressed ALDH1A1 
and who didn’t are 1.85(95%CI: 0.94, 3.63) and 1.40(95%CI: 0.68, 2.86) and they are not significant 
(p<0.05). The cut-off points in deciding positive and negative ALDH1 genes expression are not uniform, 
with some original researches setting 0%, and some setting 10%, or 50%. The univariate analysis for 
overall survival among ovarian cancer patients might be influenced by other factors. The sensitivity 
analysis didn’t find a significant change in pooled Hazard Ratio of overall survival for ovarian cancer 
when taking away each individual study. 
 
 
Figure 8. Association between ALDH1 genes and prognosis in Rectal Cancer 
 
Figure 8 is the forest plot to examine the association of ALDH1 genes and prognosis in rectal cancer 
patients. Four papers were included in the meta-analysis and a total of 481 rectal cancer patients were 
analyzed for disease-free survival prognosis. The heterogeneity of overall researches and subgroup 
researches was not significant (p>0.05), so fixed-model model was used in this meta-analysis. The 
papers we found for rectal cancer analysis only included ALDH1 genes expression, and the prognosis 
31 
included overall survival and disease-free survival. The pooled Hazard Ratio of disease-free survival 
for rectal cancer patients is 2.57 (95%CI: 1.15, 5.73) between patients who expressed ALDH1 genes 
and who didn’t express it. This pooled Hazard Ratio for disease-free survival is significant (p=0.02). In 
this meta-analysis, the unadjusted DFS hazard ratio was calculated from Kaplan-Meier curve. But in 
the original paper, multivariate Cox analysis showed postoperative ALDH1 independently predicted 
poor prognosis in patients with rectal cancer who received radiochemotherapy (P=0.0095). The pooled 
disease-free survival of rectal cancer patients indicated that ALDH1 is a significant poor prognosis 
predictor for disease-free survival. This result provides a potential prognosis research field for rectal 
cancer, which hasn’t been investigated much by researchers. The sensitivity analysis didn’t find 
significant change in pooled Hazard Ratio of disease free survival when sequentially excluding each 
study from the meta-analysis. 
 
 
Figure 9.1 Association between ALDH1A2 and prognosis in different cancers 
 
Figure 9.1 is the forest plot to examine the association of ALDH1A2 expression status and overall 
survival in cancer patients. Five papers specified ALDH1A2 expression in five different cancer types 
including breast cancer, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung 
cancer and oropharyngeal squamous cancer and a total number of 5905 patients were analyzed for 
overall survival. The heterogeneity is significant in this meta-analysis (I2>50%, p<0.001), and the 
prognosis effect vary across the different cancer types. Four papers reported overall survival by 
univariate analysis, and the pooled Hazard Ratio might be influenced by other covariates that were not 
controlled in the analysis. The pooled Hazard Ratio of overall survival in cancer patients is 0.85 (95%CI: 
0.60, 1.20) between patients with positive ALDH1A2 expression and negative ALDH1A2 expression 





Figure 9.2 Association between ALDH1A3 and prognosis in different cancers 
 
This forest plot examines the association between overall survival of different cancer patients and 
ALDH1A3 expression. Ten papers analyzed ALDH1A3 expression association and were included in this 
meta-analysis, with a total number of 8205 patients. The ten papers analyzed six types of cancers 
including bladder cancer, breast cancer, gastric cancer, glioma, non-small cell lung cancer and prostate 
cancer. The heterogeneity of the ten papers was significant (I2>50%, p<0.001) and random-effect model 
was used to calculate the pooled Hazard Ratio. The pooled Hazard Ratio for overall survival of cancer 
patients is 1.63 (95%CI: 1.02, 2.62) between patients with positive ALDH1A3 expression and patients 
with negative ALDH1A3 expression. And the pooled Hazard Ratio is statistically significant (p<0.001). 
Based on the availability of original researches found, subgroups analysis wasn’t conducted to examine 
the prognosis effect for each cancer types. The pooled Hazard Ratio indicated a significant poor 
prognosis effect in cancer patients who expressed ALDH1A3. Therefore, ALDH1A3 might be a potential 
poor prognosis predictor for cancer patients. 
 
Figure 9.3 Association between ALDH1L1 and prognosis in different cancers 
This forest plot is an attempt to see if there’s association between ALDH1L1 expression and overall 
survival in cancer patients including liver cancer, gastric cancer, breast cancer and non-small cell lung 
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cancer. Four papers were included in this analysis with a total number of 6353 patients of four different 
cancer types. The heterogeneity is significant among the four original researches (I2>50%, p<0.001), 
and the different cancer types may lead to various overall survival. A better scrutiny of each Hazard 
Ratio for overall survival, we can see the prediction of good prognosis or poor prognosis for different 
cancer types vary. The pooled Hazard Ratio of overall survival between cancer patients with positive 
ALDH1L1 expression and patients with negative ALDH1L1 expression is 1.00 (95%CI: 0.65, 1.54). 
Even if the pooled HR didn’t show prognosis effect, more investigation is worthwhile to disclose the 
association. 
 
Table 3 Hazard Ratio for association between ALDH1 gene expression status and prognosis of cancers, specified by Random effect 
model and Fixed effect model calculation 
Levels of Synthesized Information 
No. of Studies (No. of 
Patients) 
Random Effects Hazard 
Ratio Estimates (95%CI) 
Fixed Effects Hazard 
Ratio Estimates (95%CI) 
Overall Survival of Breast Cancer 25(11,983) 1.83(1.46, 2.28) 1.09(1.03, 1.16) 
ALDH1 and adjusted OS in breast cancer 11(2,640) 2.52(1.77, 3.60) 1.84(1.61, 2.10) 
ALDH1 and unadjusted OS in breast cancer 6(1,233) 0.98(0.57, 1.67) 1.09(0.82, 1.44) 
ALDH1A1 and adjusted OS in breast cancer 5(4,210) 2.65(0.98, 7.12) 0.89(0.83, 0.97) 
ALDH1A3 and adjusted OS in breast cancer 2(320) 1.75(1.02, 2.97) 1.70(1.09, 2.66) 
ALDH1A3 and unadjusted OS in breast cancer 2(3,580) 1.09(0.97, 1.22) 1.09(0.97, 1.22) 
Disease Free Survival of Breast Cancer 21(4,703) 2.15(1.45, 3.18) 1.06(0.99, 1.13) 
ALDH1 and adjusted DFS in breast cancer 8(1,418) 2.00(1.24, 3.23) 1.01(0.90, 1.12) 
ALDH1 and unadjusted DFS in breast cancer 8(1,517) 2.28(0.58, 8.94) 3.62(2.83, 4.61) 
ALDH1A1 and adjusted DFS in breast cancer 5(1,768) 2.02(0.86, 4.74) 0.93(0.85, 1.01) 
Overvall Survival of Colon Cancer 9(2,135) 2.13(0.97, 4.66) 1.64(1.26, 2.15) 
Overall Survival of esophageal squamous carcinoma 6(652) 1.22(0.82, 1.81) 1.23(0.99, 1.54) 
ALDH1 and adjusted OS in esophageal carcinoma 2(217) 1.49(1.07, 2.08) 1.49(1.07, 2.08) 
ALDH1 and unadjusted OS in esophageal carcinoma 4(435) 1.14(0.61, 2.13) 1.05(0.78, 1.42) 
Disease Free Survival of Esophageal Carcinoma 3(412) 1.84(0.70, 4.84) 0.90(0.66, 1.23) 
Disease Free Survival of HNSCC 5(388) 1.04(0.55, 1.96) 1.12(0.83, 1.52) 
Overall Survival of NSCLC 8(2995) 1.94(1.23, 3.07) 1.11(0.99, 1.23) 
Disease Free Survival of NSCLC 5(937) 1.32(0.65, 2.66) 1.32(0.65, 2.66) 
Overall Survival of Ovarian Cancer 9(1,257) 1.48(1.12, 1.96) 1.10(0.92, 1.32) 




Figure 10.1 Funnel plot of ALDH1 genes expression and breast cancer overall survival, as a means of assessing publication bias.  
Figure 10.2 Funnel plot of ALDH1 genes expression and breast cancer disease-free survival 
 
Figure 10.1 and Figure 10.2 are funnel plots to check the existence of publication bias for meta-analysis. 
Y-axis, logHR, represents size of studies and X-axis represents the Hazard Ratio for each individual 
study. The ideal situation of no publication bias will present large studies plotting near pooled Hazard 
Ratio and small studies spreading randomly on both sides, which creates a funnel-shaped distribution. 
Figure 10.1 indicated no obvious evidence of publication bias for association between ALDH1 and 
overall survival in breast cancer. Figure 10.2 showed minor evidence of publication bias for association 
between ALDH1 and disease-free survival in breast cancer as there was one outlier point in the funnel 





Figure 10.3 Funnel plot of ALDH1 genes expression and overall survival in colon cancer 
Figure 10.4 Funnel plot of ALDH1 genes expression and overall survival in esophageal squamous carcinoma 
Figure 10.5 Funnel plot of ALDH1 genes expression and disease-free survival in esophageal squamous carcinoma 
 
No significant publication bias was found from the three studies, which suggested the pooled Hazard 





Figure 10.6 Funnel plot of ALDH1 genes expression and disease-free survival in HNSCC 
 
This funnel plot indicated no obvious publication bias for disease-free survival of head and neck 
squamous carcinoma cancer with ALDH1 genes expression. 
 
 
Figure 10.7 Funnel plot of ALDH1 genes expression and overall survival in non-small cell lung cancer 
Figure 10.8 Funnel plot of ALDH1 genes expression and disease-free survival in non-small cell lung cancer 
 
Figure 10.7 suggested minor evidence for publication bias in checking association of ALDH1 and 
overall survival in non-small cell lung cancer. There was outlier study that made the funnel asymmetric. 
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Figure 10.8 suggested no obvious evidence for publication bias in association of ALDH1 and disease-
free survival in non-small cell lung cancer. The funnel was in a symmetric shape and studies scattered 





Figure 10.9 Funnel plot of ALDH1 genes expression and overall survival in ovarian cancer 
Figure 10.10 Funnel plot of ALDH1 genes expression and disease-free survival in rectal cancer 
 
Funnel plots 10.9 and 10.10 didn’t show significant publication bias, which were strong evidence of 
ALDH1 being a prognosis predictor for patients with ovarian cancer and rectal cancer. 
 
 
Figure 10.11 Funnel plot of ALDH1A2 and prognosis in cancer patients 
Figure 10.12 Funnel plot of ALDH1A3 and prognosis in cancer patients 
Figure 10.13 Funnel plot of ALDH1L1 and prognosis in cancer patients 
 
 
The three funnel plots provided information as whether more investigation was required to examine the 





In recent studies, a particular sub-group of tumor cells are believed to play a critical role in cancer, 
which is called cancer stem cells(CSCs) or tumor initiating cells(TICs). The most important 
characteristics of CSCs are enhanced tumorigenicity and the capacity for self renewal and self 
differentiation. The ALDH activity has been identified and can separate CSCs from a series of cancer 
types [23, 173]. The ALDH isozymes actively participate in various physiological responses including 
drug resistance and RA formation, also ALDH isozymes can protect stem cells from toxic endogenous 
and exogenous aldehydes.  Hence ALDHs can be a potential stem cell marker, or cancer stem cell 
predictor [174]. Among the nineteen ALDH isoenzymes, ALDH1A1 was extensively considered to 
interact with cancer stem cells including breast cancer and non-small cell lung cancer. Studies on murine 
hematopoietic stem cells, murine progenitor pancreatic cells, and breast cancer stem cells demonstrated 
that ALDH1A3 expression may result in aldefluor positivity, which exerted influence in regulation CSCs 
[63]. Previous researches have indicated the potential of ALDHs to predict cancer patients’ outcome 
because of its role in CSCs.  
 
Unlike Relative Risk or Odds Ratio, Hazard Ratio is the time-to-event analysis instead of event analysis. 
In order to study the prognosis effect of ALDH in cancer patients, estimation is conducted to evaluate 
the proportion of cancer patient group who would survive in a given length of time under the same 
ALDH status from a set of observed survival time interval. And Kaplan-Meier curve is constructed in 
the already published papers to display the survival functions. The Cox model is used to simultaneously 
explore the effects of different risk factors related to cancer patients’ survival, or different combinations 
of covariates to cancer patients death [175].  As to the clinical outcomes of overall survival or disease-
free survival, the Cox Regression Model is based on the assumption that the predictor variable are 
constant over time and additive in log scale. The Cox model can allow isolation the ALDH expression 
status from other contributable variables to survival outcome, by adjusting other covariates effects. 
 
Meta-analysis can provide a more accurate estimation of researched effect, because meta gives weight 
to each studies based on the sample size and include individual researches into meta-analysis. The 
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reason why a meta-analysis is conducted on ALDH prognosis effect on cancer patient is that it can 
address certain practical difficulties that may beset anyone trying to make sense of prediction of ALDH 
prognosis influence. The validity of this meta-analysis study depends on the quality of the systematic 
review on the survival analysis considering ALDH expression in cancer patients. This meta-analysis 
study aims to assess all relevant studies on ALDH and cancer patients’ survival analysis, presents a 
decent summary of existing researches, looks for the presence of heterogeneity and unbiased synthesis 
among these published studies, and explore the robustness of the main findings using sensitivity analysis. 
To overcome bias, a rigorous systematic review is conducted to quantitatively evaluate survival 
outcomes and ALDH1 expression status. A well-executed meta-analysis requires a complete unbiased 
collection of all the original studies of acceptable quality that examine prognosis of ALDH1 on cancer 
patients. Sensitivity analysis will help explore the effect of excluding various categories of studies and 
how consistent the results are among studies[176].  
 
This meta-analysis found ALDH1 genes expression is association with poor overall survival of breast 
cancer (HR: 1.83) and disease-free survival of breast cancer (HR: 1.61). The significant association 
provided evidence of ALDH1 families as prognosis predictor for breast cancer patients. The adjusted 
Hazard Ratio provided an even stronger association for ALDH1 genes prognosis. This conclusion is 
consistent with most of published studies, but some studies did conclude different way. The 
inconsistency with conclusion from Liu [135] might be attributed to specific breast cancer, triple-
negative breast cancer, and also because of the experiment design of gene expression from stromal cells 
or cancer cells, or the analysis with different cohort effect sizes.  
 
This meta-analysis also found ALDH1 genes expression is associated with poor overall survival in colon 
cancer (HR: 2.13). This association is not significant, however the adjusted overall survival is 
significantly associated with ALDH1 genes expression status. The conclusion that ALDH1 genes are 
poor prognosis of colon cancer is consistent with previous researches. For patients with esophageal 
squamous carcinoma, this meta-analysis discovered the insignificant association of ALDH1 genes with 
poor overall survival (HR: 1.22) and with disease-free survival (HR: 1.84). The researches included 
39 
proposed controversial prognosis effect of ALDH1. The controversy of conclusion may be related to 
the different treatment received by esophageal squamous carcinoma [106] or age group [105]. The 
expression of ALDH1 in esophageal squamous carcinoma patients required further investigation in 
order to draw meaningful conclusion and check the prognosis effect. A most unique and important 
finding in this meta-analysis study is that ALDH1 is a significant poor prognosis of disease-free survival 
in rectal cancer patients (HR: 2.57).  The result is consistent with each of the four original researches 
found. Researches can be conducted simultaneously for colon cancer and rectal cancer, which is 
believed to originate from normal stem cells. 
 
Another important finding of this study is the association of ALDH1 genes expression with poor 
prognosis in non-small cell lung cancer patients, both for overall survival (HR: 1.94) and disease-free 
survival (HR: 1.32). And the adjusted HR indicated a stronger association for poor prognosis. Previous 
studies that concluded in different prognosis effect may not use multivariate analysis by Cox Regression 
Model as reported in You [38]. The opposite conclusion of good prognosis of disease-free survival may 
also be due to AQUA score-defined threshold of detecting ALDH1 genes expression [157].  Because of 
the limited researches found on ALDH1A2, ALDH1A3, ALDH1B1, and ALDH1L1, this meta-analysis 
for non-small cell lung cancer prognosis didn’t include results from such ALDH1 genes. According to 
You [38], high expression of ALDH1A2 and ALDH1B1 was significantly associated with poor overall 
survival in NSCLC patients. Thus ALDH1A2 and ALDH1B1 might be good potential drug targets and 
overall survival predictor for NSCLC patients. 
 
This meta-analysis also concluded that there’s association of ALDH1 genes especially ALDH1A1 
expression with poor prognosis of overall survival in ovarian cancer patients (HR: 1.48). The significant 
poor prognosis effect is consistent with most of what original researches found [117, 120]. But some 
research concluded different way as favorable prognosis of ALDH1 for ovarian cancer [124]. In Chang’s 
study [124], high levels of ALDH1 expression was associated with endometrioid adenocarcinoma, early 
disease stage, complete response to chemotherapy and favorable survival. The cut-off point in determine 
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high and low ALDH1 expression was 20%. The prognosis markers for identifying one type cancer cells 
may not always be useful for predicting other types of cancer cells [177-179].  
 
The forest plots and funnel plots were mapped by Review Manager 5.3. To conduct a meta-analysis for 
Hazard Ratio in RevMan, logHR and se(logHR) are needed to be transformed from reported Hazard 
Ratio. Papers that either reported HR with 95%CI or HR with p-value fit the transformation calculation 
and the calculation was based on Hazard Ratio Meta-analysis Spreadsheet. This spreadsheet was 
developed by Hans Messersmith using the methods in Parmar [71] in Statistics in Medicine. Unlike 
other softwares including R, SAS, SPSS, RevMan didn’t require the 95%CI for HR reported in the 
original researches in order to meet the inclusion criteria. Because some papers may not report 95%CI 
and only reported p-value for HR if the prognosis association was not significant, this transformation 
provided method to be incorporated into meta-analysis. The method was also proposed by Parmar [71]. 
STATA and RevMan are useful in processing subgroup meta-analysis, while other softwares were more 
strict in subgroup meta. Especially RevMan is easier for sensitivity analysis to sequentially exclude 
each individual research from meta-analysis and repeat the whole process to see if pooled Hazard Ratio 
will be significantly altered. 
 
The limitations of this meta-analysis study concerns with four parts. In the first place, even if the data 
extraction method from Kaplan-Meier curve can include more validated researches, the HR calculated 
this way is unadjusted HR. Other published papers which already include the HR and 95%CI mainly 
use Cox regression model and calculate adjusted hazard ratio. This study didn’t separate adjusted HR 
and unadjusted HR into different categories. Hence the interpretation of overall HR cannot be arbitrarily 
concluded as controlling other covariates. The influence of covariates in survival in cancer patients 
remain unclear, and this can reduce the validation of overall results.  There might be a situation when 
some covariates contribute more to prognosis than ALDH1 genes expression status and not properly 
controlling the covariates can affect HR in both directions. Another problem with this data extraction 
method is the calculation of 95%CI is dependent on sample size. The studies with small sample size 
tend to have a broader 95%CI range, even if the original paper provided a significant p-value based on 
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either log-rank test or Cox regression model. There’s a tradeoff in using this data extraction method to 
include validated outcomes, and it can reduce the selection bias from inclusion process while not 
guarantee the uniform data analysis.  In addition, the cut-off points for ALDH1 genes expression status 
is not uniform, with some studies deciding positive and negative status based on their specific 
immunology results. This meta-analysis didn’t transform such criteria and standardize it. The choice of 
cut-off points will also exert influence the final result, especially when it’s not merely expression versus 
non-expression. A higher cut-off point will weaken the calculation of HR and draw it to the direction 
towards 1.This meta-analysis study didn’t cover all the cancer types found from database. Further 
original researches should be conducted on the prognosis effect and the less-studied cancer types. Next 
when interpreting the hazard ratio for a survival analysis, it’s better to take into consideration of time 
such as median survival time under scrutiny, comparison of two groups at the time point that half of 
patients experienced the event. This meta-analysis didn’t include the information about time in each 
study. Finally, the Hazard Ratio meta-analysis using Review Manager needs the log transformation for 
Hazard Ratio, 95%CI, or p-value. As such calculation is taken into consideration of sample size, some 
studies may include more than one cohort for prognosis analysis. Thus the calculation by Review 
Manager may differentiate the original HR and 95%CI provided by the original papers. 
 
Conclusions 
ALDH1 genes expression is associated with poor overall survival of breast cancer (HR: 1.83), poor 
disease-free survival of breast cancer (HR: 1.61), poor overall survival of colon cancer (HR: 2.13), poor 
overall survival of non-small cell lung cancer (HR: 1.94), poor overall survival of ovarian cancer (HR: 
1.48) and poor disease-free survival of rectal cancer (HR: 2.57). This study also found ALDH1 genes 
expression is not associated with disease-free survival of non-small cell lung cancer, overall survival 
and disease-free survival of esophageal squamous carcinoma, as well as disease-free survival of Head 
and Neck Squamous Carcinoma Cancer. Expression of ALDH1 genes predicts poor prognosis for breast 





 Describe the mechanisms of toxicity of biological, chemical, and physical stressors, including 
absorption, distribution, metabolic transformation, elimination, and genetic susceptibility. 
 This thesis describes aldehyde dehydrogenases family and its use as prognosis factors 
for certain human cancer types. Unlike mechanistic studies on ALDH1 genes, this study 
attempts to discover clinical utility of ALDH1 genes for cancer patients. 
 Review, critique, and evaluate environmental epidemiology research articles. 
 The meta-analysis is a comprehensive review of already published papers on ALDH1 
genes families and human cancers.  
 Synthesize information from a variety of environmental health and related studies 
 The meta-analysis analyzed and organized data from each related papers and made a 
comprehensive summary to assess all possible original researches concerning survival 
analysis of ALDH1 genes among cancer patients. 
 Use epidemiological, exposure assessment, toxicological and statistical techniques in assessing 
the risks associated with environmental hazards in the working, residential, and community 
environment. 
 The statistical analysis helps in discovering the ALDH1A1, ALDH1A2, ALDH1A3, 
ALDH1B1, ALDH1L1 level and activity in association with breast cancer, lung cancer 
and esophageal cancer or other cancer types among humans. It shed light on how 
enzymes may work as prognosis biomarkers for these cancers. 
 Explain the interrelationships among a multitude of factors that can influence a public health 
problem. 
 The study aims to find out the correlation or association between ALDH1 genes 
expression and prognosis for cancer patients. It is more important to improve the life 
quality of cancer patients, including preventing the recurrence of cancer for humans. 
By identifying the prognosis effect, this study can disclose the clinical potential of 
ALDH1 families as marker for prognosis prediction. This can provide recommendation 
for personalized treatment for cancer patients. 
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Innovation of This Meta-Analysis 
 Previous Systematic Review and Meta-Analysis for prognosis effect of ALDH1 genes on cancer 
studies didn’t provide enough information about categorical difference in six ALDH1 genes. 
The majority of papers put the six ALDH1 genes together without specifying the isozymes. This 
meta-analysis specified ALDH1 isozymes into six subtypes as ALDH1, ALDH1A1, ALDH1A2, 
ALDH1A3, ALDH1B1, ALDH1L1, ALDH1L2 (no prognosis research) and then combine 
isozymes together and carry out the analysis as ALDH1 family. It’s a more comprehensive 
systematic review compared to targeting at only one isozyme and its prognosis effect. 
 The HR calculation based on Kaplan-Meier curve data extraction provides a more validated 
result for meta-analysis study. Excluding the survival analysis paper that didn’t calculate HR 
can bring in bias for the entire study results. Including the unadjusted calculated HR can give 
weight to such studies that meet inclusion criteria for this meta-analysis studies. This estimation 
method extends validated study sample for prognosis effect of ALDH1 genes. 
 This study shed enlightening light on exploration and examination of whether ALDH1 can be a 
clinical biomarker in predicting prognosis as well as metastasis. Its clinical significance for 
survival prediction caters to the trend of personalized medicine and arising genetic sequencing 
skill utility. The conclusion of the study enriches the clinical utility of ALDH1 genes, and can 
work as new mechanism for drug treatment and cancer progression pathway. This meta-analysis 
also provides basis for prognosis effect of other ALDH genes like ALDH2, and the cancer types 
cover some of the most common one. By categorizing cancer type, the prognosis prediction has 
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